Exciting News! AcoraMed Wins the 2025 Global Cardiovascular Technology Innovation Award!

May 16, 2025 10:12 CST Updated 10:12

AccuPulse

Developer of products in the field of cardiac electrophysiology

On May 15, 2025, the Global Cardiovascular Conference was held at the Exhibition Center Conference Center of Zhongguan Village National Independent Innovation Demonstration Zone in Beijing, China.

AccuPulse Medical Technology Co., Ltd. has won the "2025 Global Cardiovascular Technology Innovation Award" with its approved series of cardiac pulsed field ablation (PFA) products!This breakthrough achievement also marks AccuPulse's technological breakthrough and development vitality in the electrophysiology field.

Reason for winning:

AccuPulse Cardiac Pulse Ablation System, independently developed by AccuPulse Medical Technology Co., Ltd. in Suzhou, was validated by 17 electrophysiology experts from eight research centers in China, with an immediate success rate of 100% during procedures and an effectiveness rate of 87.7% at the 12-month follow-up.

The AccuPulse Cardiac Pulse Ablation System is compatible with the mainstream 3D mapping platforms currently available in the market, aligning with current clinical operation habits, shortening the learning curve for younger operators, and improving clinical work efficiency. Its 7.5F adjustable loop diameter circular catheter, paired with the AccuBlator® multi-channel pulse ablation instrument, can flexibly adapt to different anatomical structures. The system’s unique intelligent contact sensing and electrode flexibility selection functions make atrial fibrillation ablation safer, more precise, and more efficient.

AccuPulse has established nearly 10 product pipelines based on new technologies such as pulsed field ablation (PFA) and innovative three-dimensional mapping.Covering the complete process of ablation diagnosis and treatment for arrhythmias such as atrial fibrillation and premature ventricular contractions.

April 2023,AccuPulse Medical Technology Co.Ltd's self-developed Accupulse Pulsed Electric Field Ablation SystemSuccessfully completed the enrollment of all clinical studies, andApproved for marketing by the National Medical Products Administration on April 29, 2025.

AccuPulse's three-dimensional mapping system innovatively integrates an intelligent magnetic and electric dual positioning system, which will be combined with the next-generation intracardiac echocardiography (ICE) function in the future to achieve ultrasound magnetic and electric triple positioning technology.This technology will be perfectly integrated with the pulsed ablation system, effectively eliminating clutter and noise issues, addressing the challenges of precise positioning and contact for pulsed ablation catheters, and is expected to improve surgical success rates, reduce operation time, providing patients with a safer, more effective, and more precise treatment experience.

This honor belongs to every member of AccuPulse, clinical experts, and partners!AccuPulse will continue to focus on the cardiac electrophysiology field, committed to providing patients with a one-stop solution for atrial fibrillation treatment.